Key result
Early-phase trials of vascular-disrupting agents revealed a cardiovascular toxicity profile including hypertension, arrhythmias, and myocardial infarction, which were dose-limiting.
Why the study?
What are the cardiovascular toxicity profiles of small-molecule vascular-disrupting agents (VDAs) in preclinical and clinical trials?
What are the cardiovascular toxicity profiles of small-molecule vascular-disrupting agents (VDAs) in preclinical and clinical trials?
Vascular-disrupting agents are associated with significant cardiovascular toxicities, necessitating careful baseline risk assessment and monitoring in collaboration with cardiology.
No takes yet. Share an insight, caveat, or question.
VDAs require baseline CV risk assessment and cardiology collaboration for monitoring; confirms dose-limiting toxicities in early-phase trials and guides future development.
Subbiah et al. (2011) conducted a review in Solid tumors. Vascular-disrupting agents (VDAs) was evaluated on Cardiovascular toxicities. Early-phase trials of vascular-disrupting agents revealed a cardiovascular toxicity profile including hypertension, arrhythmias, and myocardial infarction, which were dose-limiting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: